Abstract
Background: Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization. Case report: We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis. Conclusions: We believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.
Original language | English (US) |
---|---|
Article number | 64 |
Journal | Journal of Medical Case Reports |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2023 |
Keywords
- Anaphylactoid
- Bamlanivimab
- Case report
- Etesevimab
- Infusion reaction
- Monoclonal antibody
ASJC Scopus subject areas
- General Medicine